NCT06000423

Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: Female
• Age: 15 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text message service

Conditions

• Bleeding
• Contraceptive Device; Complications

Interventions

Type	Name	Description
DRUG	Tranexamic acid	1300mg TXA taken three times per day for five days
OTHER	Placebo	Placebo pills taken three times daily for five days.

Timeline

• Start date: 2024-01-23
• Primary completion: 2025-08-13
• Completion: 2025-08-14
• First posted: 2023-08-21
• Last updated: 2025-08-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study